Cargando…
Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
SIMPLE SUMMARY: After the surgical removal of colorectal cancer (CRC), residual cancer cells undetectable by standard blood tests and imaging studies are responsible for cancer recurrence. Currently, chemotherapy is often administered after surgery to eradicate residual cancer cells, a decision guid...
Autores principales: | Chakrabarti, Sakti, Kasi, Anup Kumar, Parikh, Aparna R., Mahipal, Amit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265001/ https://www.ncbi.nlm.nih.gov/pubmed/35804850 http://dx.doi.org/10.3390/cancers14133078 |
Ejemplares similares
-
The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review
por: Chakrabarti, Sakti, et al.
Publicado: (2020) -
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021) -
Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
por: Chakrabarti, Sakti, et al.
Publicado: (2020) -
Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions
por: Chakrabarti, Sakti, et al.
Publicado: (2020) -
ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
por: Masfarré, Laura, et al.
Publicado: (2021)